Research analysts who have asked questions during Cresco Labs earnings calls.
Aaron Grey
Alliance Global Partners
3 questions for CRLBF
Also covers: AFCG, AGFY, CGC +22 more
AP
Andrew Partheniou
Stifel
3 questions for CRLBF
Also covers: CYBN, GTBIF, TCNNF
SF
Scott Fortune
ROTH MKM
3 questions for CRLBF
Also covers: , AYRWF, CURLF +10 more
ML
Michael Lavery
Piper Sandler & Co.
2 questions for CRLBF
Also covers: BGS, BYND, CELH +25 more
CB
Chad Britnell
Morgan Stanley
1 question for CRLBF
Also covers: ONON, TJX
Derek Dley
Canaccord Genuity
1 question for CRLBF
Also covers: TCNNF
FG
Frederico Gomes
ATB Capital Markets
1 question for CRLBF
Also covers: AAWH, ACB, AYRWF +9 more
Gerald Pascarelli
Needham & Company
1 question for CRLBF
Also covers: AGFY, CELH, COCO +8 more
GM
Glenn Mattson
Ladenburg Thalmann & Co. Inc.
1 question for CRLBF
Also covers: BLNE, JUSHF, KOPN +8 more
LH
Luke Hannan
Canaccord Genuity Group Inc.
1 question for CRLBF
Also covers: CWBHF, DOOO, GIL +1 more
MM
Matt McGinley
Needham
1 question for CRLBF
Also covers: AAWH, AYRWF, GTBIF +2 more
Pablo Zuanic
Zuanic & Associates
1 question for CRLBF
Also covers: ACB, AFCG, CGC +14 more
Recent press releases and 8-K filings for CRLBF.
Cresco Labs CEO Comments on Cannabis Rescheduling to Schedule III
CRLBF
New Projects/Investments
Accounting Changes
- Cresco Labs CEO Charlie Bachtell stated that President Trump's action to reschedule cannabis from a Schedule I to Schedule III substance marks the most consequential moment in the history of U.S. cannabis.
- This rescheduling is expected to remove the unfair tax burden on cannabis companies, allowing them to reinvest in new infrastructure and job growth.
- It also lays essential groundwork for banking reform and access to U.S. capital markets, which are critical steps for aligning federal policy with the industry's scale.
- The CEO believes this action will normalize and professionalize the industry, acknowledging cannabis as medicine and paving the way for comprehensive medical research and responsible regulation.
Dec 18, 2025, 7:22 PM
Cresco Labs Launches Flagship Flower Brand in Germany
CRLBF
Product Launch
New Projects/Investments
- Cresco Labs has made its first commercial entry into the European Union by launching its Cresco-branded flower in Germany.
- This launch is part of an expanded growth strategy to pilot new investment platforms beyond U.S. cannabis, leveraging Germany's status as one of the fastest-growing regulated cannabis markets.
- The company is partnering with Blossom, an EU GMP-certified manufacturing partner in Portugal, to introduce three signature flower products, which are now available via prescription through licensed pharmacies across Germany.
Nov 12, 2025, 11:30 AM
Cresco Labs Reports Q3 2025 Financial Results and Debt Refinancing
CRLBF
Earnings
Debt Issuance
New Projects/Investments
- Cresco Labs reported Q3 2025 revenue of $165 million, an 8.3% decrease compared to Q3 2024, primarily due to price compression and increased competition in key markets, partially offset by retail growth in Ohio.
- The company posted a net loss of $22 million for Q3 2025, which included a $16 million loss for debt extinguishment related to debt refinancing. Despite this, Adjusted EBITDA for the quarter was $40 million, representing a 24.1% margin.
- As of September 30, 2025, Cresco Labs had $79 million in cash, cash equivalents, and restricted cash. The company refinanced its senior secured term credit facility on August 13, 2025, securing a new $325 million loan at 12.5% interest maturing in August 2030, which repaid the prior $360 million facility.
- Cresco Labs is pursuing new growth opportunities, including expansion into Kentucky through management services agreements and an upcoming product launch in Germany, alongside new dispensaries in Ohio.
Nov 7, 2025, 10:21 PM
Cresco Labs Reports Q3 2025 Financial Results and Debt Refinancing
CRLBF
Earnings
Debt Issuance
New Projects/Investments
- Cresco Labs reported Q3 2025 revenue of $165 million and a net loss of $22 million. The company achieved Adjusted EBITDA of $40 million with an Adjusted EBITDA margin of 24.1% for the quarter ended September 30, 2025.
- On August 13, 2025, Cresco Labs refinanced its senior secured term credit facility, closing a new $325 million loan with a 12.5% interest rate and extending the debt maturity to 2030. As of September 30, 2025, the company held $79 million in cash, cash equivalents, and restricted cash.
- Management highlighted new growth opportunities, including new dispensaries in Ohio, expansion into Kentucky, and an upcoming product launch in Germany.
Nov 5, 2025, 11:30 AM
Cresco Labs Closes $325 Million Senior Secured Term Loan Refinancing
CRLBF
Debt Issuance
- Cresco Labs Inc. completed a $325 million senior secured term loan refinancing on August 13, 2025.
- The new loan bears an interest rate of 12.5% per annum and matures on August 13, 2030.
- This transaction replaces the company's prior $360 million facility, reducing total debt and extending the maturity period.
- The new facility offers enhanced flexibility to prepay up to $125 million at a reduced premium and contains no equity or convertible features.
Sep 22, 2025, 4:46 PM
Quarterly earnings call transcripts for Cresco Labs.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more